ApoL1 and the Immune Response of Patients with Systemic Lupus Erythematosus

Curr Rheumatol Rep. 2017 Mar;19(3):13. doi: 10.1007/s11926-017-0637-9.

Abstract

Purpose of review: Systemic lupus erythematosus (SLE) confers up to a 50-fold increased risk of cardiovascular disease (CVD), and African Americans with SLE experience accelerated damage accrual and doubled cardiovascular risk when compared to their European American counterparts.

Recent findings: Genome-wide association studies have identified a substantial signal at 22q13, now assigned to variation at apolipoprotein L1 (APOL1), which has associated with progressive nondiabetic nephropathy, cardiovascular disease, and many immune-associated renal diseases, including lupus nephritis. We contend that alterations in crucial APOL1 intracellular pathways may underpin associated disease states based on structure-functional differences between variant and ancestral forms. While ancestral APOL1 may be a key driver of autophagy, nonconserved primary structure changes result in a toxic gain of function with attenuation of autophagy and an unsupervised pore-forming feature. Thus, the divergent intracellular biological pathways of ancestral and variant APOL1 may explain a worsened prognosis as demonstrated in SLE.

Keywords: Autoimmunity; Autophagy; Functional genetics.

Publication types

  • Review

MeSH terms

  • Apolipoprotein L1
  • Apolipoproteins / genetics*
  • Apolipoproteins / physiology
  • Autophagy / genetics
  • Cardiovascular Diseases / genetics
  • Cardiovascular Diseases / immunology
  • Genetic Predisposition to Disease
  • Genome-Wide Association Study
  • Humans
  • Lipoproteins, HDL / genetics*
  • Lipoproteins, HDL / physiology
  • Lupus Erythematosus, Systemic / genetics*
  • Lupus Erythematosus, Systemic / immunology*
  • Lupus Nephritis / genetics
  • Lupus Nephritis / immunology

Substances

  • APOL1 protein, human
  • Apolipoprotein L1
  • Apolipoproteins
  • Lipoproteins, HDL